Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Cumberland Pharmaceuticals: No Reason To Turn Bullish After Q3

2018-01-22 seekingalpha
But the company is buying those revenues: earnings are down, and the legacy portfolio is collapsing. (35-1)

Cumberland Pharmaceuticals' (CPIX) CEO A.J. Kazimi on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Thank you for joining the Cumberland Pharmaceuticals Third Quarter 2017 Financial Results and Corporate Update. Please be advised that this conference call is being recorded at the company’s request and will be archived on Cumberland’s website for one week from today’s date. (2-0)

Don't Get Suckered Into Cumberland Pharmaceuticals

2017-09-21 seekingalpha
CPIX's bull case looks impressive on its face: huge cash balance, trailing twelve-month profits, four quarters of double-digit revenue growth, and a diversified drug portfolio, including four phase II candidates. (108-0)

Deals of the day-Mergers and acquisitions

2017-09-13 reuters
Sept 13 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Wednesday:

Form 8.3 - Clinigen Group plc

2017-08-18 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - AXA INVESTMENT MANAGERS : Clinigen Group Plc

2017-08-18 londonstockexchange
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

Form 8.3 - Clinigen Group plc

2017-08-18 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

Hargreave Hale LTD : Form 8.3 - Clinigen Group PLC

2017-08-18 londonstockexchange
AMENDED PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

Form 8.3 - Clinigen Group Plc

2017-08-18 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - Clinigen Group Plc

2017-08-18 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - Clinigen Group plc

2017-08-18 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.5 (EPT/RI) - Clinigen Group Plc

2017-08-18 londonstockexchange
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Form 8.3 - Clinigen Group plc

2017-08-17 londonstockexchange
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - Clinigen Group Plc

2017-08-17 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - [Clinigen Group plc]

2017-08-17 londonstockexchange
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.


CUSIP: 00B89J241